Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) Research & Development (2016 - 2025)

Vycor Medical has reported Research & Development over the past 11 years, most recently at $4201.0 for Q2 2025.

  • Quarterly Research & Development rose 85.64% to $4201.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $9963.0 through Dec 2025, down 43.31% year-over-year, with the annual reading at $9963.0 for FY2025, 34.99% down from the prior year.
  • Research & Development was $4201.0 for Q2 2025 at Vycor Medical, down from $5762.0 in the prior quarter.
  • Over five years, Research & Development peaked at $7550.0 in Q2 2023 and troughed at $1825.0 in Q3 2021.
  • The 4-year median for Research & Development is $5508.0 (2023), against an average of $4846.5.
  • The largest YoY upside for Research & Development was 194.98% in 2024 against a maximum downside of 70.03% in 2024.
  • A 4-year view of Research & Development shows it stood at $6705.0 in 2021, then crashed by 66.44% to $2250.0 in 2023, then soared by 194.98% to $6637.0 in 2024, then tumbled by 36.7% to $4201.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Research & Development are $4201.0 (Q2 2025), $5762.0 (Q1 2025), and $6637.0 (Q4 2024).